Eicosapentaenoic Acid-Enriched High-Density Lipoproteins Exhibit Anti-Atherogenic Properties
Tanaka N, Irino Y, Shinohara M, Tsuda S, Mori T, Nagao M, Oshita T, Mori K, Hara T, Toh R, Ishida T, Hirata KI
Circulation journal : official journal of the Japanese Circulation Society · 39 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- In vitro/mechanistic study (classified by our AI screen)
- Studied in
- Cells or lab samples
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
- Government
- Japan Society for the Promotion of Science
- Grants
- Japan Society for the Promotion of Science (15K09121)
Based on 1 listed funder(s).
Publication
- Published
- 2017-06-22 · Circ J · vol. 82 · issue 2 · pp. 596–601
- Publisher
- Japanese Circulation Society
- Cited
- 54 citations · more than 93% of similar papers · 3.5× the field average
- Impact
- Top 10% most cited in its field
- References
- 29 works
- Access
- Open access (free to publish)
- Research areas
- Fatty Acid Research and Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Antioxidant Activity and Oxidative Stress
- Keywords
- Eicosapentaenoic acid, Chemistry, Internal medicine, Biochemistry, Medicine, Fatty acid, Polyunsaturated fatty acid
- MeSH
- cells, cultured, humans, inflammation, cholesterol, eicosapentaenoic acid, fatty acids, unsaturated, lipoproteins, hdl, vascular cell adhesion molecule-1, atherosclerosis, human umbilical vein endothelial cells
12 authors
From JP
- Nobuaki K. TanakaKobe University
- Yasuhiro IrinoKobe University
- Masakazu ShinoharaKobe University
- Shigeyasu TsudaKobe University
- Takeshige MoriKobe University
- Manabu NagaoKobe University
Abstract
Background
It has previously been reported that oral administration of purified eicosapentaenoic acid (EPA) generates EPA-rich high-density lipoprotein (HDL) particles with a variety of anti-inflammatory properties. In this study, the mechanism underlying the anti-atherogenic effects of EPA-rich HDL using reconstituted HDL (rHDL) was investigated.
Methods and results
rHDL was generated by the sodium cholate dialysis method, using apolipoprotein A-1 protein, cholesterol, and various concentrations of EPA-phosphatidylcholine (PC) or egg-PC. Increased EPA-PC contents in rHDL resulted in decreased particle size. Next, the effects of rHDL containing various amounts (0-100% of total PC) of EPA-PC on vascular cell adhesion molecule-1 (VCAM-1) expression in human umbilical vein endothelial cells (HUVECs) was examined. Cytokine-stimulated VCAM-1 expression was inhibited in a dose-dependent manner based on the amount of EPA-PC in rHDL. Surprisingly, the incubation of HUVECs with EPA-rich rHDL resulted in the production of resolvin E3 (RvE3), an anti-inflammatory metabolite derived from EPA. Incubation with EPA-PC alone did not adequately induce RvE3 production, suggesting that RvE3 production requires an endothelial cell-HDL interaction. The increased anti-inflammatory effects of EPA-rich HDL may be explained by EPA itself and RvE3 production. Furthermore, the increase in EPA-PC content enhanced cholesterol efflux.
Conclusions
The EPA-enriched HDL particles exhibit cardioprotective properties via the production of anti-inflammatory lipid metabolites and the increase in cholesterol efflux.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.